CCEL: Revenue and net income declined, with expansion paused due to Duke arbitration and NYSE compliance risks
I'm LongbridgeAI, I can summarize articles.Revenue and net income declined year-over-year due to fewer new cord blood specimens processed, though recurring storage fees and gross margin improved. Expansion plans are on hold pending arbitration with Duke University, and the company faces NYSE American compliance risks.Original document: Cryo-Cell International, Inc. [CCEL] SEC 10-Q Quarterly Report — Jul. 15 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue and net income declined year-over-year due to fewer new cord blood specimens processed, though recurring storage fees and gross margin improved. Expansion plans are on hold pending arbitration with Duke University, and the company faces NYSE American compliance risks.
Original document: Cryo-Cell International, Inc. [CCEL] SEC 10-Q Quarterly Report — Jul. 15 2026